Latest News

Elizabeth Nally, MBBS, highlights the impact of long-term immunotherapy toxicity and the need for patient-informed approaches to treatment decisions.

In this episode of The UroOnc Minute, Mark D. Tyson, II, MD, MPH, discusses the importance of BCG maintenance therapy in NMIBC and shares strategies for navigating treatment barriers and toxicity.

Keith Xavier, MD, discusses the role of Altaviva in treating men with overactive bladder and urge urinary incontinence, including patient selection, clinical considerations, and its place among third-line therapies.

Abraham Morgentaler, MD, joins Neil Baum, MD, to discuss the historical origins of the belief that testosterone drives prostate cancer and the new framework presented in his recent Journal of Urology publication.

The registrational trial will compare ivonescimab plus enfortumab vedotin vs pembrolizumab plus enfortumab vedotin for locally advanced or metastatic urothelial carcinoma.

Amy Pearlman, MD, and guests Larry Lipshultz, MD, and Elliot Justin, MD, explore the potential of wearable technology to advance the diagnosis, monitoring, and optimization of sexual health for both men and women.

The next-generation implant is designed to extend the implant longevity from 10 years to 15 years.

A recap of the FDA submissions and regulatory decisions in urology from July 2026.

Alan Bryce, MD, breaks down the key prostate cancer studies that he believes are going to change practice from ASCO 2026.

Recent data suggest that bladder cancer burden is increasing across age groups, with a disproportionate rise among younger women.

Four Urology Times Clinical Forums show that ARPI safety, drug interactions, and cognitive effects, not efficacy alone, guide mCSPC therapy selection.

The approval is supported by data from the phase 3 PSMAddition trial.

Joshua Lang, MD, MS discusses how emerging biomarkers may help personalize treatment decisions while highlighting barriers to precision oncology in prostate cancer.